In the specific context of HER2-low breast cancer, the presence of tumor heterogeneity should be acknowledged, as it may contribute to partial treatment responses and the low expression of HER2 requires a delivery system that does not rely exclusively on HER2-mediated uptake, such as lipid nanoparticles or exosomes. This evidence concerns the gene ERBB2 and breast carcinoma.